S-Equol in Alzheimer's Disease (SEAD) Trial

• Status: Completed
• Trial end date: 2016-04-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine if S-equol could benefit persons with Alzheimer's Disease (AD).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Russell Swerdlow, MD
• Collaborator: Ausio Pharmaceuticals, LLC
• Treatments: Equol

Criteria

Inclusion Criteria:

• Very mild (CDR 0.5) or mild (CDR 1) AD at time of last KU ADC assessment

• Have a study partner

• Speak English as primary language

Exclusion Criteria:

• No viable study partner

• Report a potentially confounding, serious medical risk such as type 1 diabetes, cancer, or a recent cardiac event (i.e. heart attack, angioplasty, etc.)

• Use any type of estrogen replacement therapy